continue today Thank you, we Alexis, our make. discuss to us quarter you morning, third and everyone. joining and progress to good for results the Thank
increase a prescription year-over-year. year-over-year retail million, at net was in pleased XX% represents are revenue We report increase represents XX% equivalents. by quarter. a and million, was another to U.S. increase which year-over-year driven $XX.X which revenue in strong a XX% Total $XX came
of the new-to-brand of continued in disciplined European releases NEXLIZET U.S. months publications Cardiology our Outcomes medications, clinical Congress strategy. impressive of well of upon We're August. ACC our the our our build CLEAR at to prescriptions NEXLETOL of life-saving the execution of momentum reflects proud readout since recently robustness following and data, the by the are X data business into in pleased strength at Society second efficacy our our also the cadence believe commercial bolstered additional and the this of year, half most the March, as We then, of as in and in
From quarter March through into end prescriptions quarter. the grew momentum from the second of third with new-to-brand the September, continuing XX%
let through Next, me highlights from walk quarter. the additional
submitting in labels XX% As I date growth our last already we even growth originally mentioned, include NEXLETOL March to demonstrating regulatory announce risk in PDUFA and NEXLIZET reduction cardiovascular anticipated FDA quarter, of or our a with approval ahead is of of After to year-over-year, delivered of which we the we're quarter with consistent XX, RPE pleased when approval. submission continued filings indication. narrow third our acceptance
of Lastly, label to our in the and reduction approval track, regulatory cardiovascular XXXX. risk the we continue submission anticipate half of review in first on EU remains its
analyses to further August, at about Society quarter, we Cardiology risk the of our new We presented the reduction. disseminate continued support data products. benefits the the educate Outcomes in third CLEAR from During cardiovascular market that X new to European of
not The cardiovascular value acid adverse first major multiple the acid of over first that just reinforcing in long-term reduces time. demonstrated analysis events, use bempedoic bempedoic but reducing total events the
to diabetes major statins that underscores diabetes. and also not safety analysis is adverse diabetes, patients events feature demonstrated without and key compared its a does both new onset The increase the reduced first bempedoic efficacy and in acid patients which and rate differentiating with with second in time of cardiovascular to
of the population in constituted large increased CLEAR proportion for risk that we events, a Outcomes. at Patients with IVs, who prevention studied primary are cardiovascular
from it safety and analysis is first-in-class finding further These therapies action. existing highlighting LDL-cholesterol and continue of lowering to demonstrate efficacy this the bempedoic So mechanism differentiating important. its acid, of
organization cardiovascular say which growth. not our that to an is that is is to on make we've on receive update. include to accelerated to moment will new label end, is expanding we that And expanded growth is begin see overstatement when can is focus preparing organization hit our now reduction, the running you To the we've prescription following real risk sales ground our we entire our this catalyst. the It laying always label. our of said focused approval groundwork gone for that been to the And changes so
conversations data. aligns to and that utilization Next, with off coverage CLEAR wins improved payers are continuing our ongoing Outcomes with for criteria management pay with recent
of It progress. is look continued these not and which common, are payers, to regional see we national to forward types encouraging mid-cycle with changes and
event, announced health care we from practitioners more the benefit a Amgen the and the who strategic to Finally, increasing ACC at high a awareness help with treatment. LDL of of with cholesterol could of of goal collaboration screening campaign identify screening cardiac importance launch to risk patients easily
receiving which data, we we the will of to patients benefit we our in well group subset in and get much by broad label, addressable next Outcomes characterized CLEAR when year. our believe narrow quite our current patients. our The label From label only significantly on CVOT perspective, remove indicated cardiovascular Based population new a small increase have is a March patient is current a of we reduction will both as and larger risk as potential primary secondary anticipate commercial a add that indication for limitations. populations
XX statin our with therapies about only maximally million are patients HeFH for now, ASCVD secondary Right documented prevention or indicated tolerated who a and are therapy. on
in reflect March by us XX million anticipate be And additional data enable an patients we for be our will patients. high-risk focus. CLEAR primary these XX total prevention that primary million label, XX, indicated to Outcomes and will our new Our
of the millions patients, therapies of who goals being high There currently upside. risk look who and are We represent alone. another on patients are and XX unable additional their current able those in million achieve the an forward patients in are LDL-cholesterol for still U.S., address event untreated potential to to needs to
will our performance. that, hand over I for detailed our Halladay, it Chief quarter to Officer, Ben Financial third now overview a more With of
